Inhaled nitric oxide therapy in neonates and children: reaching a European consensus.
Inhaled nitric oxide (iNO) was first used in neonatal practice in 1992 and has subsequently been used extensively in the management of neonates and children with cardiorespiratory failure. This paper assesses evidence for the use of iNO in this population as presented to a consensus meeting jointly organised by the European Society of Paediatric and Neonatal Intensive Care, the European Society of Paediatric Research and the European Society of Neonatology. Consensus Guidelines on the Use of iNO in Neonates and Children were produced following discussion of the evidence at the consensus meeting.
Macrae
Duncan J
DJ
Royal Brompton Hospital, Sydney Street, SW3 6NP London, U.K. d.macrae@rbh.nthames.nhs.uk
Field
David
D
Mercier
Jean-Christophe
JC
Møller
Jens
J
Stiris
Tom
T
Biban
Paolo
P
Cornick
Paul
P
Goldman
Allan
A
Göthberg
Sylvia
S
Gustafsson
Lars E
LE
Hammer
Jürg
J
Lönnqvist
Per-Arne
PA
Sanchez-Luna
Manuel
M
Sedin
Gunnar
G
Subhedar
Nim
N
D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D007231:Infant, Newborn; D007234:Infant, Premature; D009569:Nitric Oxide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D010547:Persistent Fetal Circulation Syndrome / Q000188:drug therapy; D012128:Respiratory Distress Syndrome / Q000188:drug therapy; D016896:Treatment Outcome
D001993:Bronchodilator Agents; D009569:Nitric Oxide